Boosting the antitumor effect of doxorubicin by combined correction of hemostasis
| Autor: | L. V. Lyubina, V. P. Lepekhin, T. Yu. Mikhal'skaya, V. M. Zyablitskii, V. P. Baluda |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Vascular wall
Pathology medicine.medical_specialty Platelet aggregation business.industry General Medicine Heparin medicine.disease Lung surface Primary tumor General Biochemistry Genetics and Molecular Biology Hemostasis Cancer research medicine Doxorubicin PULMONARY CARCINOMA business medicine.drug |
| Zdroj: | Bulletin of Experimental Biology and Medicine. 119:198-200 |
| ISSN: | 1573-8221 0007-4888 |
| DOI: | 10.1007/bf02445878 |
| Popis: | The size of the primary tumor and number of metastases to the lungs in mice with Lewis pulmonary carcinoma treated with doxorubicin were, respectively, 3 and 2.2 times less than in the control. Injection of doxorubicin and heparin led to an 8-fold reduction of the tumor. The number of animals with detected metastases to the lungs and the mean number of metastases per animal were decreased. Supplementation of doxorubicin therapy with a complex of drugs correcting platelet aggregation and the antithrombogenic properties of the vascular wall resulted in a reduction of the number of metastases on the lung surface in comparison with the control and with the animals treated with doxorubicin alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink